| abstract |
The present invention provides transdermal compositions comprising a phosphodiesterase type-5 inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In the pharmaceutical composition, But are not limited to, cocamidopropyl betaine, sodium lauroamphoacetate, quaternium-60, isostearamidopropyl morpholine lactate, dipropylene glycol, glycol, and mixtures thereof, wherein the enhancer is selected from the group consisting of: Characterized in that the phosphodiesterase type-5 inhibitor (PDE-5 inhibitor) and the enhancer are present in a ratio of about 20: 1 to 2: 1 and a method for administering the same to a subject . |